1Yamada K,Furusawa S,Saito K,et al.Concurrent use of granulocyte colony stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia:a pilot study[J].Leukemia, 1995,9:10-14.
2Cheson BD,Bennett JM,Kopecky KJ,et al.Revised recommendations of the International Working Group for diagnosis,standardization of response criteria,treatment outcomes,and reporting standards for ther- apeutic trials in acute myeloid leukemia[J].J Clin Oncol,2003,21:4642-4649.
5Saito K,Nakamura Y,Aoyagi M,et al.Low-dose cytarabine and acla-rubicin in combination with granulocyte colonystimulation factor (CAG regimen) for previously treated patientswith relapsed or pri-mary resistant acute myelogenous leukemia(AML) and previouslyuntreated elderly patientswith AML,secondary AML,and refractoryanemia with excess blasts in transformation[J].Int J Hematol,2000,71 (3):238-244.
6Nakamura Y,Arai Y,Gunji H,et al.WT1 gene expression in patients with acute myelogenous leukemia or high riskmyelodysplastic syndrome successfully treated with CAG regimen[J].Rinsho Ketsueki,2002,43(10):960-962.
